Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World check: does nivolumab help after bladder cancer surgery?

NCT ID NCT05779592

First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 4 times

Summary

This study is observing about 400 people in Japan who received the drug nivolumab after surgery for muscle-invasive urothelial carcinoma, a type of bladder or urinary tract cancer. Researchers are tracking how long patients stay cancer-free, side effects, and how the treatment is actually used in everyday medical practice. The goal is to see if nivolumab works well outside of clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Local Institution

    City, State, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nivolumab

What this could lead to

If successful, this study could confirm that nivolumab is effective and safe as an adjuvant therapy for muscle-invasive urothelial carcinoma in real-world settings.

What could go wrong

This is an observational study, not a controlled trial, so results may be less definitive. It only includes Japanese patients, so findings may not apply to other populations.

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.